The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...

US stock futures rose slightly on Friday (July 18) after the S&P 500 closed at a record high in the previous session, with ...

The growing number of fatalities is raising questions about the future of Sarepta’s therapies and the regulatory path for ...

The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...

Sarepta Therapeutics (SRPT) stock falls as the FDA reviews if the company's gene therapy Elevidys should remain on the market following patient deaths. Read more here.

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.

Sarepta Therapeutics was approached for comment by Clinical Trials Arena but did not respond before publication. This comes ...

The U.S. Food and Drug Administration will request Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...